| Year |
Citation |
Score |
| 2023 |
Benzidia I, Robitaille C, Abualsaud A, McDonald L, Lesenko L, Morin JF, Langleben D, Kahn SR, Hirsch A. Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension. Thrombosis Research. 229: 139-145. PMID 37453256 DOI: 10.1016/j.thromres.2023.07.002 |
0.405 |
|
| 2022 |
Benza RL, Langleben D, Hemnes AR, Vonk Noordegraaf A, Rosenkranz S, Thenappan T, Hassoun PM, Preston IR, Ghio S, Badagliacca R, Vizza CD, Lang IM, Meier C, Grünig E. Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Review : An Official Journal of the European Respiratory Society. 31. PMID 36198418 DOI: 10.1183/16000617.0061-2022 |
0.48 |
|
| 2022 |
Langleben D, Orfanos SE, Fox BD, Messas N, Giovinazzo M, Catravas JD. The Paradox of Pulmonary Vascular Resistance: Restoration of Pulmonary Capillary Recruitment as a for True Therapeutic Success in Pulmonary Arterial Hypertension. Journal of Clinical Medicine. 11. PMID 35956182 DOI: 10.3390/jcm11154568 |
0.511 |
|
| 2022 |
Humbert M, Simonneau G, Pittrow D, Delcroix M, Pepke-Zaba J, Langleben D, Mielniczuk LM, Escribano Subias P, Snijder RJ, Barberà JA, Klotsche J, Meier C, Hoeper MM. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 41: 716-721. PMID 35305871 DOI: 10.1016/j.healun.2022.02.002 |
0.36 |
|
| 2021 |
Benza RL, Ghofrani HA, Grünig E, Hoeper MM, Jansa P, Jing ZC, Kim NH, Langleben D, Simonneau G, Wang C, Busse D, Meier C, Ghio S. Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. PMID 34353714 DOI: 10.1016/j.healun.2021.06.020 |
0.533 |
|
| 2021 |
Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, Grünig E, Jansa P, Klinger JR, Langleben D, McLaughlin VV, Meyer GMB, Ota-Arakaki J, Peacock AJ, Pulido T, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. The Lancet. Respiratory Medicine. PMID 33773120 DOI: 10.1016/S2213-2600(20)30532-4 |
0.439 |
|
| 2020 |
Ghofrani HA, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, et al. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine. 178: 106220. PMID 33540340 DOI: 10.1016/j.rmed.2020.106220 |
0.495 |
|
| 2020 |
Hoeper MM, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, et al. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine. 177: 106241. PMID 33422952 DOI: 10.1016/j.rmed.2020.106241 |
0.513 |
|
| 2020 |
Simonneau G, Ghofrani HA, Corris PA, Rosenkranz S, Grünig E, White J, McLaughlin VV, Langleben D, Meier C, Busse D, Kleinjung F, Benza RL. Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. Pulmonary Circulation. 10: 2045894020973124. PMID 33354316 DOI: 10.1177/2045894020973124 |
0.455 |
|
| 2020 |
Klinger JR, Chakinala MM, Langleben D, Rosenkranz S, Sitbon O. Riociguat: clinical research and evolving role in therapy. British Journal of Clinical Pharmacology. PMID 33242341 DOI: 10.1111/bcp.14676 |
0.472 |
|
| 2020 |
Ghofrani HA, Grünig E, Jansa P, Langleben D, Rosenkranz S, Preston IR, Rahaghi F, Sood N, Busse D, Meier C, Humbert M. Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). Pulmonary Circulation. 10: 2045894020942121. PMID 32728421 DOI: 10.1177/2045894020942121 |
0.461 |
|
| 2020 |
Vassiliou AG, Keskinidou C, Kotanidou A, Frantzeskaki F, Dimopoulou I, Langleben D, Orfanos SE. Knockdown of bone morphogenetic protein type II receptor leads to decreased aquaporin 1 expression and function in human pulmonary microvascular endothelial cells. Canadian Journal of Physiology and Pharmacology. 98: 834-839. PMID 32687728 DOI: 10.1139/cjpp-2020-0185 |
0.312 |
|
| 2020 |
Hirani N, Brunner NW, Kapasi A, Chandy G, Rudski L, Paterson I, Langleben D, Mehta S, Mielniczuk L. Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. The Canadian Journal of Cardiology. 36: 977-992. PMID 32682511 DOI: 10.1016/J.Cjca.2019.11.041 |
0.454 |
|
| 2020 |
Benza RL, Corris PA, Klinger JR, Langleben D, Naeije R, Simonneau G, Ghofrani HA, Jansa P, Rosenkranz S, Scelsi L, Thenappan T, Raina A, Meier C, Busse D, Hoeper MM. Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. International Journal of Cardiology. 317: 188-192. PMID 32461118 DOI: 10.1016/J.Ijcard.2020.05.044 |
0.429 |
|
| 2020 |
Semalulu T, Rudski L, Huynh T, Langleben D, Wang M, Fritzler MJ, Pope J, Baron M, Hudson M. An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. Seminars in Arthritis and Rheumatism. PMID 32245697 DOI: 10.1016/J.Semarthrit.2020.02.013 |
0.504 |
|
| 2020 |
Langleben D, Channick R, Delcroix M, Galiè N, Ghofrani A, Jansa P, Mehta S, Pulido T, Souza R, Simonneau G, Sastry BKS, Torbicki A, Martin N, Perchenet L, Sitbon O. Safety And Efficacy Of Macitentan In Elderly Patients With Pulmonary Arterial Hypertension (Pah): Insights From Seraphin Journal of the American College of Cardiology. 75: 2090. DOI: 10.1016/S0735-1097(20)32717-0 |
0.479 |
|
| 2020 |
Vassiliou AG, Keskinidou C, Kotanidou A, Frantzeskaki F, Dimopoulou I, Langleben D, Orfanos SE. Decreased bone morphogenetic protein type II receptor and BMP-related signalling molecules' expression in aquaporin 1-silenced human pulmonary microvascular endothelial cells. Hellenic Journal of Cardiology. DOI: 10.1016/J.Hjc.2020.04.003 |
0.338 |
|
| 2019 |
Moghaddam N, Swiston JR, Weatherald J, Mielniczuk L, Kapasi A, Hambly N, Langleben D, Brunner NW. Impact of saline loading at cardiac catheterization on the classification and management of patients evaluated for pulmonary hypertension. International Journal of Cardiology. PMID 31784045 DOI: 10.1016/J.Ijcard.2019.11.104 |
0.434 |
|
| 2019 |
McLaughlin VV, Channick R, De Marco T, Farber HW, Gaine S, Galié N, Krasuski RA, Preston I, Souza R, Coghlan JG, Frantz RP, Hemnes A, Kim NH, Lang IM, Langleben D, et al. Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents. Chest. PMID 31738929 DOI: 10.1016/J.Chest.2019.10.043 |
0.507 |
|
| 2019 |
Langleben D, Orfanos SE, Giovinazzo M, Schlesinger RD, Naeije R, Fox BD, Abualsaud AO, Blenkhorn F, Rudski LG, Catravas JD. Pulmonary capillary surface area in supine exercising humans: demonstration of vascular recruitment. American Journal of Physiology. Lung Cellular and Molecular Physiology. PMID 31242024 DOI: 10.1152/Ajplung.00098.2019 |
0.404 |
|
| 2019 |
Langleben D, Gaine S, Sitbon O, Channick R, Chin K, Scala LD, Galiè N, Hoeper M, McLaughlin V, Preiss R, Rubin L, Simonneau G, Tapson V, Ghofrani H, Lang I. The Impact Of Time From Diagnosis At Baseline On Long-Term Outcome In The Griphon Study: Selexipag In Pulmonary Arterial Hypertension (Pah) Canadian Journal of Cardiology. 35. DOI: 10.1016/J.Cjca.2019.07.180 |
0.504 |
|
| 2019 |
McLaughlin V, Channick R, Marco TD, Farber H, Gaine S, Galie N, Krasuski R, Preston I, Souza R, Coghlan J, Frantz R, Hemnes A, Kim N, Lang I, Langleben D, et al. Prostacyclin International Expert Panel Consensus-Based Recommendations For The Use Of Selexipag In Patients With Pulmonary Arterial Hypertension Chest. 156. DOI: 10.1016/J.Chest.2019.08.1023 |
0.572 |
|
| 2018 |
Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, Kawut SM, Langleben D, Lumens J, Naeije R. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. The European Respiratory Journal. PMID 30545976 DOI: 10.1183/13993003.01900-2018 |
0.438 |
|
| 2018 |
Langleben D, Orfanos SE. Pulmonary capillary recruitment in exercise and pulmonary hypertension. The European Respiratory Journal. 51. PMID 29545319 DOI: 10.1183/13993003.02559-2017 |
0.505 |
|
| 2018 |
Benza R, Ghio S, Grünig E, Jing Z, Langleben D, Ghofrani H, Meier C, Busse D. Effect Of Riociguat On Right Ventricular Function In Patients With Pulmonary Arterial Hypertension Chest. 154. DOI: 10.1016/J.Chest.2018.08.962 |
0.574 |
|
| 2017 |
Benza RL, Farber HW, Frost AE, Ghofrani HA, Gómez-Sánchez MA, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper MM. REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. Journal of Heart and Lung Transplantation. 37: 513-519. PMID 29223470 DOI: 10.1016/J.Healun.2017.11.006 |
0.348 |
|
| 2017 |
Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. The European Respiratory Journal. 50. PMID 28889107 DOI: 10.1183/13993003.02425-2016 |
0.465 |
|
| 2017 |
Langleben D, Orfanos S. Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis. Pulmonary Circulation. 7: 588-597. PMID 28632001 DOI: 10.1177/2045893217714231 |
0.534 |
|
| 2017 |
Zhan Y, Burstein B, Abualsaud AO, Nosair M, Hirsch AM, Lesenko L, Langleben D. Right ventricular ST-elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension. Pulmonary Circulation. 7: 555-558. PMID 28597772 DOI: 10.1177/2045893217704435 |
0.419 |
|
| 2017 |
Harel F, Langleben D, Provencher S, Fournier A, Finnerty V, Nguyen QT, Letourneau M, Levac X, Abikhzer G, Guimond J, Mansour A, Guertin MC, Dupuis J. Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. European Journal of Nuclear Medicine and Molecular Imaging. PMID 28236024 DOI: 10.1007/s00259-017-3655-y. |
0.526 |
|
| 2017 |
Gall H, Ghofrani H, Humbert M, Simonneau G, Grünig E, Klose H, Halank M, Langleben D, Mielniczuk LM, Vachiéry J, Wirtz H, Lange T, Escribano P, Helmersen DS, Pepke-Zaba J, et al. Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry European Respiratory Journal. 50. DOI: 10.1183/1393003.Congress-2017.Pa3534 |
0.516 |
|
| 2017 |
Hoeper MM, Ghofrani H, Benza RL, Corris PA, Gibbs J, Klinger JR, Langleben D, McLaughlin V, Peacock A, Rosenkranz S, Vonk-Noordegraf A, White R, Kleinjung F, Meier C, Simonneau G. REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal European Respiratory Journal. 50. DOI: 10.1183/1393003.Congress-2017.Pa2417 |
0.503 |
|
| 2017 |
Hoeper MM, Corris PA, Ghofrani H, Klinger JR, Langleben D, Naeije R, Simonneau G, Jansa P, Rosenkranz S, Grünig E, Scelsi L, Meier C, Busse D, Benza RL. Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study European Respiratory Journal. DOI: 10.1183/1393003.Congress-2017.Oa1980 |
0.59 |
|
| 2017 |
Thenappan T, Hoeper M, Corris P, Ghofrani H, Klinger J, Langleben D, Naeije R, Simonneau G, Jansa P, Rosenkranz S, Grünig E, Scelsi L, Meier C, Busse D, Benza R. Effect of Riociguat on Pulmonary Arterial Compliance in Patients With Pulmonary Arterial Hypertension (PAH) in the Respite Study Chest. 152. DOI: 10.1016/J.Chest.2017.08.1040 |
0.59 |
|
| 2016 |
Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. PMID 28190787 DOI: 10.1016/J.Healun.2016.12.012 |
0.572 |
|
| 2016 |
Hoeper MM, Klinger JR, Benza RL, Simonneau G, Langleben D, Naeije R, Corris PA. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respiratory Medicine. S18-S22. PMID 27887774 DOI: 10.1016/j.rmed.2016.11.001 |
0.397 |
|
| 2016 |
Limoges M, Langleben D, Fox BD, Shear R, Wieczorek P, Rudski LG, Hirsch AM, Schlesinger RD, Lesenko L. Pregnancy as a possible trigger for heritable pulmonary arterial hypertension. Pulmonary Circulation. 6: 381-3. PMID 27683615 DOI: 10.1086/686993 |
0.414 |
|
| 2016 |
Fox BD, Shtraichman O, Langleben D, Shimony A, Kramer MR. Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. The Canadian Journal of Cardiology. PMID 27378592 DOI: 10.1016/j.cjca.2016.03.004 |
0.454 |
|
| 2016 |
Ghofrani HA, Humbert M, Langleben D, Schermuly R, Stasch JP, Wilkins MR, Klinger JR. Riociguat: Mode of action and clinical development in pulmonary hypertension. Chest. PMID 27263466 DOI: 10.1016/J.Chest.2016.05.024 |
0.568 |
|
| 2016 |
Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Humbert M. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. The Lancet. Respiratory Medicine. PMID 27067479 DOI: 10.1016/S2213-2600(16)30019-4 |
0.517 |
|
| 2016 |
Dupuis J, Harel F, Langleben D, Provencher S, Fournier A, Nguyen QT, Finnerty V, Letourneau M, Levac X, Mansour A, Abikhzer G, Guimond J. MOLECULAR IMAGING OF THE HUMAN PULMONARY VASCULAR ENDOTHELIUM IN PULMONARY HYPERTENSION: THE PULMOBIND SAFETY AND PROOF OF PRINCIPLE TRIAL Journal of the American College of Cardiology. 67: 2045. DOI: 10.1016/S0735-1097(16)32046-0 |
0.508 |
|
| 2016 |
Granton J, Bergot E, Boonstra A, Subias PE, Galiè N, Langleben D, Lemarié JC, Pfister T, Simonneau G, Sitbon O, Delcroix M. Long-Term Safety and Tolerability of a New Formulation of Epoprostenol in Pulmonary Arterial Hypertension (PAH) Patients: Final Results from EPITOME-2 Journal of Heart and Lung Transplantation. 35. DOI: 10.1016/J.Healun.2016.01.1031 |
0.534 |
|
| 2016 |
Langleben D, Beghetti M, Channick R, Chin K, DiScala L, Gaine S, Ghofrani H, Hoeper M, Lang I, McLaughlin V, Preiss R, Rubin L, Simonneau G, Sitbon O, Tapson V, et al. Selexipag For Pulmonary Arterial Hypertension Associated With Congenital Heart Disease (Pah-Chd) After Defect Correction: Insights From The Randomised Controlled Griphon Study Canadian Journal of Cardiology. 32. DOI: 10.1016/J.Cjca.2016.07.251 |
0.503 |
|
| 2015 |
Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, Langleben D, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK. ET-1 Pathway Polymorphisms Affect Outcome in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. PMID 26252367 DOI: 10.1164/Rccm.201501-0196Oc |
0.448 |
|
| 2015 |
Granton J, Langleben D, Kutryk MB, Camack N, Galipeau J, Courtman DW, Stewart DJ. Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. Circulation Research. 117: 645-54. PMID 26195220 DOI: 10.1161/Circresaha.114.305951 |
0.546 |
|
| 2015 |
Afilalo J, Grapsa J, Nihoyannopoulos P, Beaudoin J, Gibbs JS, Channick RN, Langleben D, Rudski LG, Hua L, Handschumacher MD, Picard MH, Levine RA. Leaflet area as a determinant of tricuspid regurgitation severity in patients with pulmonary hypertension. Circulation. Cardiovascular Imaging. 8. PMID 25977303 DOI: 10.1161/Circimaging.114.002714 |
0.402 |
|
| 2015 |
Fox BD, Joyal D, Schlesinger RD, Eisenberg MJ, Langleben D. Evaluation of the Microstat™ sublingual PCO2 monitor in ambulatory patients. Journal of Clinical Monitoring and Computing. PMID 25753144 DOI: 10.1007/S10877-015-9686-7 |
0.381 |
|
| 2015 |
Langleben D, Galiè N, He J, Huang Y, Humbert M, Keogh A, Rubin LJ, Zhou D, Curram J, Davie N, Ghofrani HA. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 34: 338-47. PMID 25703961 DOI: 10.1016/J.Healun.2014.12.001 |
0.512 |
|
| 2015 |
Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A, Menezes F, Davie N, Ghofrani HA. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). The European Respiratory Journal. 45: 1303-13. PMID 25614164 DOI: 10.1183/09031936.00090614 |
0.554 |
|
| 2015 |
Langleben D, Orfanos SE, Giovinazzo M, Schlesinger RD, Hirsch AM, Blenkhorn F, Lesenko L, Armaganidis A, Catravas JD. Acute vasodilator responsiveness and microvascular recruitment in idiopathic pulmonary arterial hypertension. Annals of Internal Medicine. 162: 154-6. PMID 25599356 DOI: 10.7326/M14-1402 |
0.555 |
|
| 2015 |
Benza R, Frost A, Farber H, Ghofrani HA, Gómez-Sánchez M, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper M. Application of REVEAL Risk Score to Patients With PAH Receiving Riociguat in the PATENT-2 Study Chest. 148. DOI: 10.1378/Chest.2280692 |
0.301 |
|
| 2015 |
Hoeper M, Benza R, Klinger J, Simonneau G, Langleben D, Naeije R, Corris P. Rationale and Study Design of the RESPITE Trial: Riociguat Clinical Effects Studied in Pulmonary Arterial Hypertension (PAH) Patients With Insufficient Treatment Response to PDE-5 Inhibitors (PDE-5i) Chest. 148. DOI: 10.1378/Chest.2272572 |
0.535 |
|
| 2014 |
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. [Definitions and diagnosis of pulmonary hypertension]. TüRk Kardiyoloji DerneğI ArşIvi : TüRk Kardiyoloji DerneğInin YayıN OrganıDıR. 42: 55-66. PMID 25697034 |
0.441 |
|
| 2014 |
Fox BD, Azoulay L, Dell'Aniello S, Langleben D, Lapi F, Benisty J, Suissa S. The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension. The Canadian Journal of Cardiology. 30: 1633-9. PMID 25448462 DOI: 10.1016/j.cjca.2014.09.031 |
0.433 |
|
| 2014 |
Rudski LG, Bossone E, Langleben D. From the echo bed to the pulmonary vascular bed: dobutamine testing in the noninvasive laboratory. Chest. 146: 876-878. PMID 25287995 DOI: 10.1378/chest.14-0856 |
0.326 |
|
| 2014 |
Star GP, Giovinazzo M, Lamoureux E, Langleben D. Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro. Life Sciences. 118: 191-4. PMID 24607779 DOI: 10.1016/J.Lfs.2014.02.032 |
0.385 |
|
| 2014 |
Shimony A, Afilalo J, Flynn AW, Langleben D, Agnihotri AK, Morin JF, Shahian DM, Picard MH, Rudski LG. Usefulness of right ventricular dysfunction to predict new-onset atrial fibrillation following coronary artery bypass grafting. The American Journal of Cardiology. 113: 913-8. PMID 24440329 DOI: 10.1016/J.Amjcard.2013.11.048 |
0.308 |
|
| 2014 |
Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, Subías PE, Galiè N, Pfister T, Lemarié J, Simonneau G. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension American Heart Journal. 167: 210-217. PMID 24439982 DOI: 10.1016/J.Ahj.2013.08.007 |
0.469 |
|
| 2013 |
Guo K, Langleben D, Afilalo J, Shimony A, Leask R, Marelli A, Martucci G, Therrien J. Anatomical considerations for the development of a new transcatheter aortopulmonary shunt device in patients with severe pulmonary arterial hypertension. Pulmonary Circulation. 3: 639-46. PMID 24618548 DOI: 10.1086/674328 |
0.445 |
|
| 2013 |
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. Journal of the American College of Cardiology. 62: D42-50. PMID 24355641 DOI: 10.1016/j.jacc.2013.10.032 |
0.442 |
|
| 2013 |
Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis and Rheumatism. 65: 3194-201. PMID 24022584 DOI: 10.1002/Art.38172 |
0.413 |
|
| 2013 |
Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ. Riociguat for the treatment of pulmonary arterial hypertension. The New England Journal of Medicine. 369: 330-40. PMID 23883378 DOI: 10.1056/Nejmoa1209655 |
0.564 |
|
| 2013 |
Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, Eisenberg MJ, Joyal D, Hudson M, Boutet K, Serban A, Masetto A, Baron M. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. The European Respiratory Journal. 42: 1083-91. PMID 23258775 DOI: 10.1183/09031936.00091212 |
0.502 |
|
| 2013 |
Star GP, Giovinazzo M, Langleben D. ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells. Microvascular Research. 85: 46-53. PMID 23142694 DOI: 10.1016/J.Mvr.2012.10.012 |
0.353 |
|
| 2013 |
Fox BD, Langleben D, Hirsch A, Boutet K, Shimony A. Step climbing capacity in patients with pulmonary hypertension. Clinical Research in Cardiology : Official Journal of the German Cardiac Society. 102: 51-61. PMID 22875547 DOI: 10.1007/S00392-012-0495-4 |
0.533 |
|
| 2013 |
Fox B, Langleben D, Hirsch AM, Schlesinger RD, Eisenberg MJ, Joyal D, Blenkhorn F, Lesenko L. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension. The Canadian Journal of Cardiology. 29: 672-7. PMID 22819360 DOI: 10.1016/J.Cjca.2012.05.013 |
0.537 |
|
| 2013 |
Shimony A, Fox BD, Langleben D, Rudski LG. Incidence and significance of pericardial effusion in patients with pulmonary arterial hypertension. The Canadian Journal of Cardiology. 29: 678-82. PMID 22717247 DOI: 10.1016/J.Cjca.2012.04.009 |
0.57 |
|
| 2013 |
Jing Z-, Galie N, Ghofrani H-, Humbert M, Langleben D, Rubin LJ, Hoeper MM, Fritsch A, Davie N, Keogh AM. Comparison of hemodynamic parameters in treatment-naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT-1 study European Heart Journal. 34: 323. DOI: 10.1093/Eurheartj/Eht307.P323 |
0.386 |
|
| 2013 |
Langleben D. The evolving paradigm of pulmonary arterial hypertension and the evolving role of endothelin-1 Life Sciences. 93. DOI: 10.1016/J.Lfs.2013.12.113 |
0.574 |
|
| 2012 |
Shimony A, Fox BD, Afilalo J, Rudski LG, Hirsch A, Langleben D. Pulmonary arterial hypertension in the elderly-clinical characteristics and long-term survival. Lung. 190: 645-9. PMID 23064491 DOI: 10.1007/s00408-012-9425-5 |
0.428 |
|
| 2012 |
Fox BD, Shimony A, Langleben D. Combination therapy in pulmonary arterial hypertension. Cardiology. 123: 41; author reply 42. PMID 22986302 DOI: 10.1159/000342061 |
0.468 |
|
| 2012 |
Ghofrani H, Galie N, Grimminger F, Humbert M, Keogh A, Langleben D, Kilama MO, Neuser D, Rubin L. Riociguat for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (PATENT-1) Chest. 142. DOI: 10.1378/Chest.1462799 |
0.545 |
|
| 2011 |
Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. The American Journal of Cardiology. 108: 1177-82. PMID 21864815 DOI: 10.1016/J.Amjcard.2011.06.021 |
0.39 |
|
| 2011 |
Shimony A, Eisenberg MJ, Rudski LG, Schlesinger R, Afilalo J, Joyal D, Dragatakis L, Hirsch A, Boutet K, Fox BD, Langleben D. Prevalence and impact of coronary artery disease in patients with pulmonary arterial hypertension. The American Journal of Cardiology. 108: 460-4. PMID 21600533 DOI: 10.1016/J.Amjcard.2011.03.066 |
0.487 |
|
| 2010 |
Langleben D, Orfanos SE. Systemic sclerosis and early-onset pulmonary hypertension. Chest. 138: 238-9. PMID 20605834 DOI: 10.1378/chest.10-0501 |
0.393 |
|
| 2010 |
Star GP, Giovinazzo M, Langleben D. Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: A potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension Microvascular Research. 80: 349-354. PMID 20594999 DOI: 10.1016/J.Mvr.2010.05.010 |
0.419 |
|
| 2010 |
Corris PA, Langleben D. The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension. The European Respiratory Journal. 35: 460-1; author reply . PMID 20123858 DOI: 10.1183/09031936.00160309 |
0.461 |
|
| 2010 |
Orfanos SE, Langleben D. Pulmonary arterial hypertension in systemic sclerosis: a distinctive endotheliopathy? The European Respiratory Journal. 35: 223-4. PMID 20044465 DOI: 10.1183/09031936.00130409 |
0.46 |
|
| 2010 |
Langleben D. Pulmonary capillary haemangiomatosis. British Heart Journal. 62: 239. PMID 18610363 DOI: 10.1136/hrt.62.3.239 |
0.447 |
|
| 2009 |
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. 54: S43-54. PMID 19555858 DOI: 10.1016/j.jacc.2009.04.012 |
0.434 |
|
| 2009 |
Langleben D, Cacoub P. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. European Journal of Clinical Investigation. 27-31. PMID 19335744 DOI: 10.1111/j.1365-2362.2009.02118.x |
0.405 |
|
| 2009 |
Star GP, Giovinazzo M, Langleben D. Effects of bone morphogenic proteins and transforming growth factor-beta on In-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells Vascular Pharmacology. 50: 45-50. PMID 18849010 DOI: 10.1016/J.Vph.2008.09.001 |
0.329 |
|
| 2008 |
Orfanos SE, Hirsch AM, Giovinazzo M, Armaganidis A, Catravas JD, Langleben D. Pulmonary capillary endothelial metabolic function in chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Haemostasis : Jth. 6: 1275-80. PMID 18532994 DOI: 10.1111/J.1538-7836.2008.03046.X |
0.548 |
|
| 2008 |
Langleben D, Orfanos SE, Giovinazzo M, Hirsch A, Baron M, Senécal JL, Armaganidis A, Catravas JD. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis and Rheumatism. 58: 1156-64. PMID 18383374 DOI: 10.1002/Art.23405 |
0.573 |
|
| 2008 |
Cacoub P, Amoura Z, Langleben D. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008]. La Revue De Medecine Interne. 29: 283-9. PMID 18243424 DOI: 10.1016/j.revmed.2007.12.005 |
0.501 |
|
| 2007 |
Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Annals of the Rheumatic Diseases. 66: 1467-72. PMID 17472992 DOI: 10.1136/Ard.2007.069609 |
0.458 |
|
| 2007 |
Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clinics in Chest Medicine. 28: 117-125. PMID 17338931 DOI: 10.1016/J.Ccm.2006.11.002 |
0.528 |
|
| 2007 |
Hooper WC, Mensah GA, Haworth SG, Black SM, Garcia JGN, Langleben D. Vascular endothelium summary statement V: Pulmonary hypertension and acute lung injury: public health implications. Vascular Pharmacology. 46: 327-329. PMID 17197249 DOI: 10.1016/J.Vph.2006.10.017 |
0.498 |
|
| 2006 |
Therrien J, Rambihar S, Newman B, Siminovitch K, Langleben D, Webb G, Granton J. Eisenmenger syndrome and atrial septal defect: nature or nurture? The Canadian Journal of Cardiology. 22: 1133-6. PMID 17102831 |
0.401 |
|
| 2006 |
Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. American Heart Journal. 152: 521-6. PMID 16923424 DOI: 10.1016/J.Ahj.2006.02.020 |
0.522 |
|
| 2006 |
Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. Journal of the American College of Cardiology. 47: 2049-56. PMID 16697324 DOI: 10.1016/j.jacc.2006.01.057 |
0.441 |
|
| 2006 |
Langleben D, Dupuis J, Langleben I, Hirsch AM, Baron M, Senécal JL, Giovinazzo M. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest. 129: 689-95. PMID 16537869 DOI: 10.1378/Chest.129.3.689 |
0.422 |
|
| 2006 |
Langleben D, Dupuis J, Hirsch A, Giovinazzo M, Langleben I, Khoury J, Ruel N, Caron A. Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. Chest. 128: 622S. PMID 16373881 DOI: 10.1378/chest.128.6_suppl.622S |
0.506 |
|
| 2006 |
Benisty JI, Folkman J, Zurakowski D, Louis G, Rich S, Langleben D, Moses MA. Matrix metalloproteinases in the urine of patients with pulmonary arterial hypertension. Chest. 128: 572S. PMID 16373832 DOI: 10.1378/chest.128.6_suppl.572S |
0.47 |
|
| 2005 |
Langleben D, Archer S, Granton J, Hirsch AM, Levy RD, Mehta S, Michelakis E, Stewart DJ. Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. Canadian Respiratory Journal : Journal of the Canadian Thoracic Society. 12: 303-15. PMID 16247528 DOI: 10.1155/2005/156750 |
0.529 |
|
| 2005 |
Langleben D, Archer S, Granton J, Hirsch AM, Levy RD, Mehta S, Michelakis E, Stewart DJ. Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. The Canadian Journal of Cardiology. 21: 909-14. PMID 16239973 |
0.445 |
|
| 2005 |
Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, Robbins IM, Shapiro S, Tapson VF, Zwicke D, DeMarco T, Schilz R, Rubenfire M, Barst RJ. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascular Pharmacology. 43: 36-9. PMID 15890561 DOI: 10.1016/j.vph.2005.03.003 |
0.437 |
|
| 2005 |
Seibold J, Badesch D, Galie N, Langleben D, Naeije R, Simonneau G, Barst R. Sitaxsentan, A Selective Endothelin-A Receptor Antagonist, Improves Exercise Capacity In Pulmonary Arterial Hypertension (Pah) Associated With Connective Tissue Disease (Ctd) Chest. 128. DOI: 10.1378/Chest.128.4_Meetingabstracts.219S |
0.497 |
|
| 2005 |
Badesch D, Galie N, Langleben D, Naeije R, Simonneau G, Barst R. Sitaxsentan Improves Time To Clinical Worsening In Patients With Pulmonary Arterial Hypertension Chest. 128. DOI: 10.1378/Chest.128.4_Meetingabstracts.160S-B |
0.571 |
|
| 2004 |
Langleben D, Brock T, Dixon R, Barst R. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. Journal of Cardiovascular Pharmacology. 44: S80-4. PMID 15838366 DOI: 10.1097/01.Fjc.0000166207.74178.D0 |
0.489 |
|
| 2004 |
Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 126: 1377-81. PMID 15486408 DOI: 10.1378/Chest.126.4.1377 |
0.546 |
|
| 2004 |
Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. 43: 5S-12S. PMID 15194173 DOI: 10.1016/j.jacc.2004.02.037 |
0.475 |
|
| 2004 |
Langleben D. Clinical relevance of endothelin B-mediated vasoconstriction in lambs with increased pulmonary blood flow. Circulation. 109. PMID 15078812 DOI: 10.1161/01.Cir.0000124886.51828.E6 |
0.364 |
|
| 2004 |
Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR. Sitaxsentan therapy for pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 169: 441-7. PMID 14630619 DOI: 10.1164/Rccm.200307-957Oc |
0.487 |
|
| 2004 |
McLaughlin VV, Hill N, Tapson V, Frost A, Langleben D, Oudiz R, Shapiro S, Robbins I, Barst RJ. Sitaxsentan Improves 6MW in Patients with Pulmonary Arterial Hypertension (PAH) Related to Connective-Tissue Diseases (CTD) Chest. 126: 7-9. DOI: 10.1378/Chest.126.4_Meetingabstracts.759S-A |
0.553 |
|
| 2004 |
Langleben D, Hirsch A, Shalit E, Lesenko L, Barst RJ, Davis MB. 1123-183 Sustained hemodynamic benefit in patients with pulmonary arterial hypertension after one-year of therapy with the selective orally-active endothelin-A receptor antagonist, sitaxsentan Journal of the American College of Cardiology. 43. DOI: 10.1016/S0735-1097(04)92122-5 |
0.529 |
|
| 2003 |
Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology. 99: 1415-1432. PMID 14639158 DOI: 10.1097/00000542-200312000-00027 |
0.563 |
|
| 2003 |
Michel RP, Langleben D, Dupuis J. The endothelin system in pulmonary hypertension. Canadian Journal of Physiology and Pharmacology. 81: 542-54. PMID 12839266 DOI: 10.1139/Y03-008 |
0.508 |
|
| 2002 |
Langleben D, Christman BW, Barst RJ, Dias VC, Galiè N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. American Heart Journal. 143: E4. PMID 12040360 DOI: 10.1067/Mhj.2002.121806 |
0.499 |
|
| 2001 |
Sebbag I, Rudski LG, Therrien J, Hirsch A, Langleben D. Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension American Journal of Cardiology. 88: 1060-1063. PMID 11704014 DOI: 10.1016/S0002-9149(01)01995-6 |
0.409 |
|
| 2001 |
Orfanos SE, Psevdi E, Stratigis N, Langleben D, Catravas JD, Kyriakidis M, Moutsopoulos HM, Roussos C, Vlachoyiannopoulos PG. Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis and Rheumatism. 44: 902-11. PMID 11315930 DOI: 10.1002/1529-0131(200104)44:4<902::Aid-Anr147>3.0.Co;2-9 |
0.49 |
|
| 2000 |
Orfanos SE, Armaganidis A, Glynos C, Psevdi E, Kaltsas P, Sarafidou P, Catravas JD, Dafni UG, Langleben D, Roussos C. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation. 102: 2011-8. PMID 11034953 DOI: 10.1161/01.Cir.102.16.2011 |
0.373 |
|
| 2000 |
Khoury J, Langleben D. Heparin-like molecules inhibit pulmonary vascular pericyte proliferation in vitro American Journal of Physiology - Lung Cellular and Molecular Physiology. 279. PMID 10926548 DOI: 10.1152/Ajplung.2000.279.2.L252 |
0.409 |
|
| 2000 |
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, ... ... Langleben D, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Annals of Internal Medicine. 132: 425-34. PMID 10733441 DOI: 10.7326/0003-4819-132-6-200003210-00002 |
0.494 |
|
| 2000 |
Langleben D, Lamoureux E, Marcotte F, Schlesinger R, Dragatakis L, Crowe MJ, Langlois Y, Lemire F, White M. Mitral stenosis obscuring the diagnosis of plexogenic pulmonary arteriopathy and familial pulmonary hypertension. Thorax. 55: 247-8. PMID 10679547 DOI: 10.1136/Thorax.55.3.247 |
0.535 |
|
| 1999 |
Langleben D, Barst RJ, Badesch D, Groves BM, Tapson VF, Murali S, Bourge RC, Ettinger N, Shalit E, Clayton LM, Jöbsis MM, Blackburn SD, Crow JW, Stewart DJ, Long W. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation. 99: 3266-71. PMID 10385501 DOI: 10.1161/01.CIR.99.25.3266 |
0.456 |
|
| 1999 |
Orfanos SE, Langleben D, Khoury J, Schlesinger RD, Dragatakis L, Roussos C, Ryan JW, Catravas JD. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in humans. Circulation. 99: 1593-9. PMID 10096936 DOI: 10.1161/01.Cir.99.12.1593 |
0.442 |
|
| 1998 |
Khoury J, Langleben D. Effects of endotoxin on lung pericytes in vitro Microvascular Research. 56: 71-84. PMID 9756730 DOI: 10.1006/Mvre.1998.2085 |
0.353 |
|
| 1998 |
Langleben D. Relearning the lessons of history: anorexigens and pulmonary hypertension. Chest. 114: 55S-57S. PMID 9676629 DOI: 10.1378/chest.114.1_supplement.55s |
0.48 |
|
| 1998 |
Oelberg DA, Marcotte F, Kreisman H, Wolkove N, Langleben D, Small D. Evaluation of right ventricular systolic pressure during incremental exercise by Doppler echocardiography in adults with atrial septal defect. Chest. 113: 1459-1465. PMID 9631778 DOI: 10.1378/Chest.113.6.1459 |
0.325 |
|
| 1997 |
Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 95: 1479-86. PMID 9118516 DOI: 10.1161/01.Cir.95.6.1479 |
0.414 |
|
| 1996 |
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The New England Journal of Medicine. 334: 296-301. PMID 8532025 DOI: 10.1056/Nejm199602013340504 |
0.454 |
|
| 1995 |
Mehta S, Stewart DJ, Langleben D, Levy RD. Short-term Pulmonary Vasodilation With l-Arginine in Pulmonary Hypertension Circulation. 92: 1539-1545. PMID 7664438 DOI: 10.1161/01.Cir.92.6.1539 |
0.511 |
|
| 1994 |
Langleben D. Familial Primary Pulmonary Hypertension Chest. 105: 13. PMID 8306801 DOI: 10.1378/Chest.105.2_Supplement.13S |
0.404 |
|
| 1994 |
Langleben D, DeMarchie M, Laporta D, Spanier AH, Schlesinger RD, Stewart DJ. Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. The American Review of Respiratory Disease. 148: 1646-50. PMID 8256914 DOI: 10.1164/ajrccm/148.6_Pt_1.1646 |
0.425 |
|
| 1993 |
Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension The New England Journal of Medicine. 328: 1732-1739. PMID 8497283 DOI: 10.1056/Nejm199306173282402 |
0.583 |
|
| 1993 |
Langleben D. Reviews, Notes, and Listings: Pulmonary Medicine: The Diagnosis and Treatment of Pulmonary Hypertension Annals of Internal Medicine. 118: 656-656. DOI: 10.7326/0003-4819-118-8-199304150-00052 |
0.527 |
|
| 1991 |
Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Annals of Internal Medicine. 114: 464-469. PMID 1994793 DOI: 10.7326/0003-4819-114-6-464 |
0.507 |
|
| 1991 |
Rush C, Langleben D, Schlesinger RD, Stern J, Wang N, Lamoureux E. Lung scintigraphy in pulmonary capillary hemangiomatosis. A rare disorder causing primary pulmonary hypertension. Clinical Nuclear Medicine. 16: 913-917. PMID 1769171 DOI: 10.1097/00003072-199112000-00007 |
0.512 |
|
| 1989 |
Langleben D, Fox RB, Jones RC, Reid LM. Effects of dimethylthiourea on chronic hypoxia-induced pulmonary arterial remodelling and ventricular hypertrophy in rats. Clinical and Investigative Medicine. MéDecine Clinique Et Experimentale. 12: 235-40. PMID 2535591 |
0.392 |
|
| 1989 |
Lisbona R, Hakim TS, Dean GW, Langleben D, Guerraty A, Levy RD. Regional pulmonary perfusion following human heart-lung transplantation. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 30: 1297-301. PMID 2502608 |
0.312 |
|
| 1988 |
Langleben D, Heneghan JM, Batten AP, Wang NS, Fitch N, Schlesinger RD, Guerraty A, Rouleau JL. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Annals of Internal Medicine. 109: 106-9. PMID 3382104 DOI: 10.7326/0003-4819-109-2-106 |
0.481 |
|
| 1988 |
Langleben D, Szarek JL, Coflesky JT, Jones RC, Reid LM, Evans JN. Altered artery mechanics and structure in monocrotaline pulmonary hypertension Journal of Applied Physiology. 65: 2326-2331. PMID 3145283 |
0.402 |
|
| 1987 |
Langleben D, Jones RC, Aronovitz MJ, Hill NS, Ou LC, Reid LM. Pulmonary artery structural changes in two colonies of rats with different sensitivity to chronic hypoxia. The American Journal of Pathology. 128: 61-6. PMID 3605313 |
0.378 |
|
| 1986 |
Langleben D, Moroz LA, McGregor M, Lisbona R. Decreased half-life of fibrinogen in primary pulmonary hypertension. Thrombosis Research. 40: 577-80. PMID 4082127 DOI: 10.1016/0049-3848(85)90295-6 |
0.507 |
|
| 1986 |
Langleben D, Carvalho AC, Reid LM. The platelet thromboxane inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension. The American Review of Respiratory Disease. 133: 789-91. PMID 3085563 |
0.319 |
|
| 1985 |
Geggel RL, Murphy JD, Langleben D, Crone RK, Vacanti JP, Reid LM. Congenital diaphragmatic hernia: arterial structural changes and persistent pulmonary hypertension after surgical repair. The Journal of Pediatrics. 107: 457-64. PMID 4032138 DOI: 10.1016/S0022-3476(85)80534-5 |
0.319 |
|
| Show low-probability matches. |